Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation
Keiichi Enjyoji(Massachusetts Institute of Technology), Jean Sévigny(Beth Israel Deaconess Medical Center), Yuan Lin(Beth Israel Deaconess Medical Center), Paul S. Frenette(Harvard University), Patricia D. Christie(Massachusetts Institute of Technology), Jan Schulte Am Esch(Beth Israel Deaconess Medical Center), Masato Imai(Beth Israel Deaconess Medical Center), Jay M. Edelberg(Massachusetts Institute of Technology), Helen Rayburn(Massachusetts Institute of Technology), Miroslaw Lech(Massachusetts Institute of Technology), David Beeler(Massachusetts Institute of Technology), Eva Csizmadia(Beth Israel Deaconess Medical Center), Denisa D. Wagner(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Simon C. Robson(Beth Israel Deaconess Medical Center), Robert Rosenberg(Massachusetts Institute of Technology)
Cited by 575
Abstract
Related Papers
Nomenclature and classification of purinoceptors.
Bertil B. Fredholm, Maria P. Abbracchio, Geoffrey Burnstock et al.|Pharmacological Reviews|1994|1.6k